NCT00444522已完成1 期
Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 主要终点
- Pharmacokinetic profile and dose proportionality
研究概览
简要总结
We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects between the ages of 18 to 55 years, inclusive.
- •Subjects with a body mass index (BMI) ≥21 and ≤
- •Subjects who speak, read, and understand English and are willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures.
- •Subjects who are willing and able to be confined to the Clinical Research Unit (CRU) and comply with the study schedule and study requirements.
- •Subjects who are in good general health as determined by a complete medical history, physical examination, 12-lead ECG, spirometry, blood chemistry profile, hematology, and urinalysis.
排除标准
- •Subjects who regularly consume large amounts of xanthine-containing substances (ie, more than 5 cups of coffee or equivalent amounts of xanthine-containing substances per day).
- •Subjects who have taken prescription or nonprescription medication (with the exception of vitamins and acetaminophen if medically necessary) within 5 days of Visit 2 (Baseline).
- •Subjects who have had an acute illness within 5 days of Visit 2 (Baseline).
- •Subjects who have received an investigational drug within 30 days (or within 5 half lives investigational drug, if >30 days) prior to Visit 2 (Baseline).
- •Subjects who have smoked tobacco within the last year.
- •Subjects who have a history within the past 2 years of drug or alcohol dependence or abuse as defined by DSM-
- •Subjects with a history of HIV positivity.
- •Subjects with a history of allergy or intolerance to benzodiazepines or related drugs (alprazolam, lorazepam, diazepam, etizolam, clonazepam, adinazolam).
- •Subjects who test positive for alcohol or have a positive urine drug screen at Visit 1 or Visit
- •Subjects who have hypotension (systolic blood pressure ≤90 mmHg, diastolic blood pressure ≤50 mmHg), or hypertension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg).
- •Subjects who have a clinically significant ECG abnormality.
- •Subjects with a history of unstable angina, syncope, coronary artery disease, myocardial infarction, congestive heart failure (CHF), stroke, transient ischemic attack (TIA), or a neurological disorder.
- •Subjects who have a history of pulmonary disease that precludes administration of Staccato Alprazolam (asthma, bronchitis, bronchospasm, emphysema).
- •Subjects who have an FEV1 less than 80% of predicted values on spirometry assessments at Visit
- •Female subjects who are breastfeeding or have a positive pregnancy test at Visit 1 or Visit
- •Female participants of child-bearing potential or within 1 year of menopause, and sexually active are excluded unless they use a medically acceptable and effective birth control method throughout the study and for 1 week following the end of the study. Medically acceptable methods of contraception include abstinence, diaphragm with spermicide, intrauterine device (IUD), condom with foam or spermicide, vaginal spermicidal suppository, surgical sterilization, and progestin implant or injection. Unacceptable methods include: birth control pills, patches, and injections, the rhythm method, withdrawal, condoms alone, or diaphragm alone.
- •Subjects who have any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.
结局指标
主要结局
Pharmacokinetic profile and dose proportionality
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Staccato Alprazolam in Panic AttackTreatment of Induced Panic AttackNCT00477451Alexza Pharmaceuticals, Inc.49
已完成
不适用
Psychopharmacology of Fear-Potentiated Startle in HumansHealthyNCT00044096National Institute of Mental Health (NIMH)225
已完成
1 期
Staccato Zaleplon Single Dose PharmacokineticsHealthyNCT00620620Alexza Pharmaceuticals, Inc.40
已完成
1 期
A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.TumorNCT05203601Shanghai Institute Of Biological Products36
已完成
1 期
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.HealthyNCT01291732Boehringer Ingelheim48